Explainer-What Novo Nordisk's weight-loss pill approval means for company, patients
Food and Drug Administration's approval of an oral version of Novo Nordisk's weight-loss drug Wegovy could potentially expand access to millions of patients and give the Danish company a much-needed fillip in the red-hot market. The first GLP-1 pill specifically for obesity, also branded as Wegovy, is a 25-mg oral formulation of semaglutide, the active ingredient in the blockbuster injectable version.
